Vir Biotechnology (VIR) Assets Average (2019 - 2026)

Vir Biotechnology's Assets Average history runs 8 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Assets Average fell 25.06% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 25.06% YoY), while the FY2025 annual figure was $1.2 billion, down 27.62% from the prior year.
• Assets Average came in at $1.0 billion for Q1 2026 at Vir Biotechnology, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.8 billion in Q2 2022 to a low of $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 151.06% in 2022 and plunged 32.1% in 2024, its largest moves.
• Vir Biotechnology's Assets Average stood at $2.7 billion in 2022, then slipped by 27.9% to $2.0 billion in 2023, then declined by 26.91% to $1.4 billion in 2024, then plunged by 30.2% to $1.0 billion in 2025, then advanced by 0.3% to $1.0 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.0 billion, $1.0 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison